POSTTRANSPLANT DIABETES IN PEDIATRIC RECIPIENTS ON TACROLIMUS

We read with interest the report by Moxey-Mims et al., "Increased Incidence of Insulin-Dependent Diabetes Mellitus in Pediatric Renal Transplant Patients Receiving Tacrolimus (FK506)", reporting a 100% incidence of posttransplant diabetes mellitus in five pediatric patients receiving tacrolimus-based immunosuppression after renal transplantation (1). Although posttransplant diabetes mellitus (PTDM) has been a commonly observed complication in adult patients receiving tacrolimus, with an initial incidence of 6.0–28.3% and a final incidence of 2.5–12.8% (2–9), it has been less common in pediatric patients, and has tended to be reversible in the overwhelming majority of the cases (10–13). The incidence of 100% reported by the authors is substantially at variance with the incidence that we and others have seen; of perhaps greater concern is the seeming lack of reversibility in most of the patients. If we are to infer from their article, three of the five children are still on insulin.

Our speculation, to be frank, is that these patients are being chronically overimmunosuppressed. Steroid withdrawal has been possible in some two thirds of pediatric recipients (11), and, in patients not withdrawn from steroids, relatively low dosages can be achieved relatively soon after transplantation. In addition, the target tacrolimus levels described by the authors are high, although the actual figures described in the patients in question are not excessively out of range.

It has been our experience, and that of others, that PTDM is largely reversible with appropriate reduction in the dosages of both tacrolimus and steroids.

RON SHAPIRO1, 5
VELMA SCANTLEBURY1
MARK L. JORDAN2
CARLOS VIVAS2
DEMETRIUS ELLIS3
SUSAN LOMBARDOZZI-LANE3
JOHN J. FUNG1
RICHARD L. SIMMONS4
THOMAS E. STARZL1
Division of Transplantation
Thomas E. Starzl Transplantation Institute
Division of Urology
Division of Pediatric Nephrology
Dept. of Surgery
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania

1 Division of Transplantation, Thomas E. Starzl Transplantation Institute.
2 Division of Urology.
3 Division of Pediatric Nephrology.
4 Dept. of Surgery.
5 Address correspondence to: Ron Shapiro, M.D., Assoc. Prof. of Surgery, Director, Renal Transplantation, Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Department of Surgery, 4C Falk Clinic, 3601 Fifth Avenue, Pittsburgh, PA 15213.

REFERENCES